The latest from Orpyx®.

Orpyx to compete in prestigious Pitch@Palace Global 3.0 Competition

Orpyx will represent Canada at Pitch@Palace Global 3.0 Competition. After being selected as one of the winners of the Pitch@Palace Commonwealth Competition, ranking as the first runner up, Orpyx has been invited to pitch its connected health platform at St. James’s Palace on December 12, 2018.

read more

Orpyx Diabetes Survey

Do you or anyone you know have diabetes? Please help us by filling out this quick survey and sharing with your networks!

read more

November is Diabetes Awareness Month!

At Orpyx, we’re focussed on science & data to end preventable diabetic foot ulcers & limb loss! Did you know over half of diabetic foot ulcers will require hospitalization and 1 in 5 people will require surgical amputation. Help raise foot health awareness this month!

read more

New clinical trial provides further evidence of the SurroSense Rx® effectiveness of protecting people with diabetes from foot ulcers

The latest clinical trial by an award-winning research group out of Manchester Metropolitan University demonstrates that people with diabetes can reduce the risk of developing foot ulcers by more than 70 per cent using the SurroSense Rx intelligent shoe insoles that send alerts to a smartwatch notifying the device user when the pressure on a particular region of their foot gets outside a healthy range.

read more

Manchester Metropolitan University Receives Award at the Diabetic Foot Study Group Scientific Meeting

The oral presentation titled “Novel Plantar Pressure-Sensing Smart Insoles Reduce Foot Ulcer Incidence in ‘High Risk’ Diabetic Patients: A Longitudinal Study” was awarded the prestigious Paul Wilson Brand Repetitive Stress Award at the 15th annual meeting of the Diabetic Foot Study Group of the EASD (European Association for the Study of Diabetes), held in Berlin, Germany September 28 – 30, 2018.

read more

New Clinical Trial Evidence of SurroSense Rx® to be Presented at EASD 2018

Results from a randomized clinical trial ran by Manchester Metropolitan University showed the SurroSense Rx provided a 71 per cent reduction in foot ulcers over an 18-month long study. Manchester Metropolitan University will be presenting their findings at EASD 2018 (European Association for the Study of Diabetes) at the Messe Berlin Exhibition Halls in Berlin-Charlottenburg, Germany on October 2, 2018.

read more

Patent granted for Orpyx® technology in the United States

Orpyx Medical Technologies Inc. announced today that the United States Patent and Trademark Office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx® product and future products, such as SurroGait Rx, in the United States.

read more

Orpyx Launches LogR™ Gen 2 Plantar Pressure System

The Orpyx LogR™ is a clinical grade plantar pressure measurement solution, making data collection outside the lab simpler and faster without compromising data quality. With 37 pressure sensors and a 9-axis IMU sampled at a frequency of 256Hz, LogR sets a high standard for data quality. The LogR inserts are light and low profile making it comfortable to wear and perfect for real world monitoring while high durability allows them to be reusable.

read more

Orpyx awarded at Pitch@Palace Commonwealth Competition

Orpyx Medical Technologies Inc. is proud to announce that it was named as the one of the winners of the Pitch@Palace Commonwealth Competition, ranking as the first runner up. The event took place as part of the Commonwealth Summit and saw entrepreneurs from across the Commonwealth come together at St. James’s Palace on April 16, 2018.

read more

Orpyx Awarded Federal Supply Schedule (FSS) Contract

Orpyx Medical Technologies Inc. announced today that the National Acquisition Center of the Department of Veterans Affairs has awarded the company a Federal Supply Schedule (FSS) contract available through Academy Medical, LLC (contract number 36F79718D0372), effective April 1, 2018. The awarding of this contract will provide all U.S. federal medical providers, including those operated by the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD) and Indian Health Services (IHS), easy access to SurroSense Rx system.

read more

Cost-effectiveness journal article published

Orpyx Medical Technologies Inc. announced today the publication of “Cost effectiveness of smart insoles in preventing ulcer recurrence for people in diabetic foot remission” in Wound Care Management. The analysis shows the cost-effectiveness of smart insoles as an adjunct to standard diabetic foot care. A pilot study completed at the University of Arizona’s Southern Arizona Limb Salvage Alliance (SALSA) provided clinical inputs for two decision tree models-one at three-months and one at eighteen-months post diabetic foot ulcer (DFU) closure, comparing current standard of care to use of the SurroSense Rx system as an adjunct to standard of care (SOC).

read more

Orpyx Technology Helps Patient with Prevention and Early Detection of Ulceration

Orpyx Medical Technologies Inc. announced today the American Society of Plastic Surgeons published “Novel Pressure-Sensing Smart Insole System Used for the Prevention of Pressure Ulceration in the Insensate Foot Case Report”. This case study explores the use of Orpyx’s SurroSense Rx® system for a patient with spina bifida, history of clubfoot, 20 operations to their right leg, and 3 years of unsuccessful wound management.

read more

World’s First Reported Case of Smart Insole Tech Managing Post-Traumatic Complications

Orpyx Medical Technologies Inc. announced today the medical journal Plastic Case Studies published “Use of the SurroSense Rx System for Sensory Substitution of the Insensate Plantar Foot Resurfaced With Latissimus Dorsi Muscle Free Flap and Skin Graft: A Retrospective Case Study”. This case study explores the use of Orpyx’s SurroSense Rx® system with a patient with the loss of protective sensation (LOPS) from a degloving injury of the right foot that was reconstructed with a latissimus dorsi free flap and skin graft.

read more

U.S. Patent No. 10,004,428 - June 2018
U.S. Patent No. 9,778,131 B2 - October 2017
U.S. Patent No. D740,950 S - October 2015
Australia Patent No. 2011320072 - May 2016
Japan Patent No. 6004444 - October 2016
New Zealand Patent No. 611197 - November 2015

Subscribe to our newsletter

* indicates required